Shots:
The company has reported dosing of the first patient in the US Â P-III (BiPASS) trial evaluating its PSMA-PET imaging agents, Illuccix and Gozellix, for use in the initial diagnosis of prostate cancer
BiPASSa P-III study enrolling 250 pts in the US and Australia to support marketing authorization of 68Ga-PSMA-PET in the pre-biopsy setting
Building…
Radiopharmaceuticals, once viewed as a niche scientific endeavor, are now revolutionizing the way we detect and treat cancer. By fusing the targeting precision of molecular medicine with the therapeutic strength of radiation, these compounds are unlocking new possibilities in oncology, bringing renewed hope to patients where conventional therapies often fall short
From early detection to…

